In September 2017, VolitionRx announced its European development plan for the Nu.Q™ colorectal cancer (CRC) frontline screening test. It will run two clinical trials (of 4,300 and 10,000 samples), which are expected to initiate in Q118 and Q218, respectively, supporting an expected CE mark and launch in Q318. VolitionRx is also participating in a three-year, 13,500-person US clinical trial including Nu.Q™ assays to support a US launch.
28 Nov 2017
VolitionRx - Big EU trials on deck
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
VolitionRx - Big EU trials on deck
Volitionrx Limited (VNRX:ASE) | 0 0 0.0%
- Published:
28 Nov 2017 -
Author:
Dr Nathaniel Calloway -
Pages:
14
In September 2017, VolitionRx announced its European development plan for the Nu.Q™ colorectal cancer (CRC) frontline screening test. It will run two clinical trials (of 4,300 and 10,000 samples), which are expected to initiate in Q118 and Q218, respectively, supporting an expected CE mark and launch in Q318. VolitionRx is also participating in a three-year, 13,500-person US clinical trial including Nu.Q™ assays to support a US launch.